Ampio Pharmaceuticals Inc

NYSE American:AMPEUnited States

Ampio Pharmaceuticals, Inc. is a biopharmaceutical company that is focused on the research, development, and advancement of immunomodulatory therapies for the treatment of pain from osteoarthritis. The Company's lead product candidate, Ampion has immunomodulatory action and anti-inflammatory effects, which provide a treatment for individuals with inflammatory conditions including, but not limited to, severe osteoarthritis of the knee (OAK); osteoarthritis related to other joints, such as hip, shoulder, ankle and hand; and the widespread inflammation associated with COVID-19 infection. Ampion is in development as an intra-articular injection treatment for severe OAK, an intravenous (IV) and inhaled treatment for hospitalized severe and/or critical COVID-19 patients, and an at-home inhalation treatment for patients with prolonged respiratory symptoms due to COVID-19, referred to as Long-COVID. Its clinical studies include AP-013, AP-017, AP-019 and AP-018.

Contact Information

Headquarters

373 Inverness Parkway, Suite 200ENGLEWOOD, CO, United States 80112

Phone

720-437-6500

Fax

720-437-6501

Executives

Independent Chairman of the Board

J. Kevin Buchi

Chief Executive Officer, Director

Michael Martino

Chief Financial Officer, Secretary

Daniel Stokely

Independent Director

Elizabeth Jobes

Independent Director

David Stevens